Please use this identifier to cite or link to this item:
Title: Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants
Authors: Zakir, Tasnim Saifudin
Meng, Tao
Carmen, Lee Ching Pei
Chu, Justin Jang Hann 
Lin, Raymond Tzer Pin 
Prabakaran, Mookkan
Keywords: Science & Technology
Life Sciences & Biomedicine
SARS-CoV-2 variants
spike RBD
neutralizing epitope
escape mutant
cross-neutralizing antibody
Issue Date: 1-Feb-2022
Publisher: MDPI
Citation: Zakir, Tasnim Saifudin, Meng, Tao, Carmen, Lee Ching Pei, Chu, Justin Jang Hann, Lin, Raymond Tzer Pin, Prabakaran, Mookkan (2022-02-01). Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. VIRUSES-BASEL 14 (2). ScholarBank@NUS Repository.
Abstract: The constant mutation of SARS-CoV-2 has led to the emergence of new variants, which call for urgent effective therapeutic interventions. The trimeric spike (S) protein of SARS-CoV-2 is highly immunogenic with the receptor-binding domain (RBD) that binds first to the cellular receptor angiotensin-converting enzyme 2 (ACE2) and is therefore the target of many neutralizing antibodies. In this study, we characterized a broadly neutralizing monoclonal antibody (mAb) 9G8, which shows potent neutralization against the authentic SARS-CoV-2 wild-type (WT), Alpha (B.1.1.7), and Delta (1.617.2) viruses. Furthermore, mAb 9G8 also displayed a prominent neutralizing efficacy in the SARS-CoV-2 surrogate virus neutralization test (sVNT) against the Epsilon (B.1.429/7), Kappa (B.1.617.1), Gamma (P.1), Beta (B.1.351), and Delta Plus (1.617.2.1) RBD variants in addition to the variants mentioned above. Based on our in vitro escape mutant studies, we proved that the mutations V483F and Y489H within the RBD were involved in ACE2 binding and caused the neutralizing evasion of the virus from mAb 9G8. The development of such a cross-reactive neutralizing antibody against majority of the SARS-CoV-2 variants provides an important insight into pursuing future therapeutic agents for the prevention and treatment of COVID-19.
ISSN: 19994915
DOI: 10.3390/v14020230
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. .pdfPublished version10.03 MBAdobe PDF



Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.